Bridgefront Capital, LLC Black Diamond Therapeutics, Inc. Call Options Transaction History
Bridgefront Capital, LLC
- $331 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$25.8 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$13.9 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$11 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.98 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$6.78 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $90.1M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...